Literature DB >> 2070366

Weight gain, increased appetite, and excessive food intake induced by carbamazepine.

Y Lampl1, Y Eshel, A Rapaport, I Sarova-Pinhas.   

Abstract

Four young patients who developed weight gain induced by carbamazepine therapy are described. The patients received the carbamazepine as anticonvulsant treatment, and soon after starting the drug, abruptly developed an increase in appetite with a concomitant increase in food intake. During a period of 2 months the patients' weights rose by between 7 and 15 kg. Dietary restriction during the carbamazepine treatment was ineffective in promoting weight loss, and loss of the excess weight was achieved only when the drug was discontinued. These patients demonstrate an as yet unpublished adverse effect of carbamazepine. In carbamazepine-induced weight gain, overeating and fat deposition must be taken into consideration as a differential diagnosis to the hitherto described water retention and edema.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070366     DOI: 10.1097/00002826-199106000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  12 in total

Review 1.  Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Authors:  Valentina Medici; Stephen A McClave; Keith R Miller
Journal:  Curr Gastroenterol Rep       Date:  2016-01

Review 2.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

3.  Carbamazepine directly inhibits adipocyte differentiation through activation of the ERK 1/2 pathway.

Authors:  E Turpin; A Muscat; C Vatier; G Chetrite; E Corruble; M Moldes; B Fève
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 4.  Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.

Authors:  Victor Biton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.

Authors:  Deborah R Leitner; Gema Frühbeck; Volkan Yumuk; Karin Schindler; Dragan Micic; Euan Woodward; Hermann Toplak
Journal:  Obes Facts       Date:  2017-10-12       Impact factor: 3.942

6.  Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium.

Authors:  Hubertus Himmerich; Dagmar Koethe; Andreas Schuld; Alexander Yassouridis; Thomas Pollmächer
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

Review 7.  Bodyweight gain and anticonvulsants: a comparative review.

Authors:  P Jallon; F Picard
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Weight gain, obesity, and psychotropic prescribing.

Authors:  Nikhil Nihalani; Thomas L Schwartz; Umar A Siddiqui; James L Megna
Journal:  J Obes       Date:  2011-01-17

9.  Evaluation of nutritional status in children with refractory epilepsy.

Authors:  S Bertoli; S Cardinali; P Veggiotti; C Trentani; G Testolin; A Tagliabue
Journal:  Nutr J       Date:  2006-04-26       Impact factor: 3.271

Review 10.  Anti-obesity activity of the marine carotenoid fucoxanthin.

Authors:  Maria Alessandra Gammone; Nicolantonio D'Orazio
Journal:  Mar Drugs       Date:  2015-04-13       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.